<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028561</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02726</org_study_id>
    <secondary_id>12657</secondary_id>
    <secondary_id>CDR0000069105</secondary_id>
    <nct_id>NCT00028561</nct_id>
  </id_info>
  <brief_title>BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Epothilone B Analog BMS 247550 in Combination With Carboplatin in Recurrent and/or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of BMS-247550 when given&#xD;
      together with carboplatin in treating patients with recurrent or refractory solid tumors.&#xD;
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining more than one drug may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of BMS-247550 when given in combination with&#xD;
      carboplatin in patients with recurrent or refractory solid tumors.&#xD;
&#xD;
      II. Determine the dose-limiting toxicity and safety of this regimen in these patients.&#xD;
&#xD;
      III. Determine the plasma pharmacokinetics of this regimen in these patients. IV. Determine,&#xD;
      preliminarily, any antitumor activity of this regimen in these patients.&#xD;
&#xD;
      V. Correlate the protein expression of survivin with the expression of other apoptotic&#xD;
      regulators, the apoptotic index, and response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of BMS-247550.&#xD;
&#xD;
      Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV&#xD;
      over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients with a complete response (CR)&#xD;
      receive 2 additional courses after achieving CR or up to a total of 6 courses. The first two&#xD;
      cohorts of 3-6 patients each receive escalating doses of BMS-247550 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at&#xD;
      least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).The third and fourth&#xD;
      cohorts of 10 patients each receive escalating doses of BMS-247550 until the MTD is&#xD;
      determined. The MTD is defined as the dose preceding that at which at least 3 of 10 patients&#xD;
      experience DLT. Once the MTD is determined for the third and fourth cohorts, 15 additional&#xD;
      patients are treated at the MTD. Patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of ixabepilone defined as the first dosage tier below the MAD in which =&lt; 1/6 patients experiences a DLT</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ixabepilone and carboplatin</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (ixabepilone, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ixabepilone, carboplatin)</arm_group_label>
    <other_name>BMS-247550</other_name>
    <other_name>epothilone B lactam</other_name>
    <other_name>Ixempra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ixabepilone, carboplatin)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ixabepilone, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ixabepilone, carboplatin)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or unresectable solid tumor for&#xD;
             which standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Lesion accessible for core or excisional biopsy if being treated at the maximum&#xD;
             tolerated dose (MTD)&#xD;
&#xD;
               -  No biliary tract dilation if radiologically guided biopsy of the liver is planned&#xD;
&#xD;
               -  No requirement for core biopsy of lung lesion that is not pleural based&#xD;
&#xD;
               -  No requirement for laparotomy or thoracotomy solely for biopsy&#xD;
&#xD;
               -  No medical condition that would preclude biopsy&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - ECOG 0-1 if being treated at the MTD&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No prior bleeding disorder or unexplained bleeding if being treated at the MTD&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  PT/PTT normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No grade 2 or greater neuropathy (sensory or motor)&#xD;
&#xD;
          -  No prior severe allergic reaction attributable to compounds containing Cremophor EL or&#xD;
             platinum agents&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No medical condition that would preclude study if being treated at the MTD&#xD;
&#xD;
          -  At least 4 week since prior immunotherapy&#xD;
&#xD;
          -  At least 24 hours since prior growth factors&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  No prior epothilone agents&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy directed at malignancy&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior wide-field radiotherapy involving 30% or more of bone&#xD;
             marrow&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No prior or concurrent St. John's Wort&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent heparin or other anticoagulants if being treated at the MTD&#xD;
&#xD;
          -  No concurrent inhibitors of cytochrome P450 3AP (CYP3A4)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Sullivan</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

